1.Lorenzati, B., Zucco, C., Miglietta, S., Lamberti, F. & Bruno G. 2010. Oral Hypoglycemic Drugs: Pathophysiological basis of their mechanism of action. Pharmaceuticals, 3: 3005- 3020.

2.Tang, C. & Zhu, X. 2012. A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. J. Mol. Model, 18: 2795–2804.

3.Hale, C. & Wang, M. 2008. Development of 11beta-HSD1 inhibitors for the treatment of type 2 Diabetes; Mini. Rev. Med. Chem., 8: 702-710.

4.Derdau, V., Fey, T. & Atzrodt, J. 2010. Synthesis of isotopically labelled SGLT inhibitors and their metabolites; Tetrahedron, 66(7): 1472–1482.

5.Rajesh, R., Naren, P., Vidyasagar, S., Unnikrishnan, Pandey, S., Varghese, M. et al. 2010. Sodium Glucose Co transporter 2 (SGLT2) Inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus. International Journal of Pharma Sciences and Research, 2: 139-147.

6.Grempler, R., Augustin, R., Froehner, S., Hildebrandt, T., Simon, E. & Mark, M. et al. 2012. Functional characterisation of human SGLT-5 as a novel kidney-specific sodiumdependent sugar transporter. FEBS Letters, 586: 248–253.

7.Zhanga, W., Welihinda, A., Mechanic, J., Ding, H., Zhu, L., Lu, Y et al. 2011. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacological Research, 63: 284–293.

8.Ohsumi, K., Matsueda, H. & Hatanaka, T. 2003. Pyrazole- O-Glucosides as Novel Na+-Glucose Cotransporter (SGLT) Inhibitors; Bioorganic & Medicinal Chemistry Letters, 13: 2269– 2272.

9.Kanai, Y., Lee, W.S., You, G., Brown, D., Hediger, M.A. & Brown, D. et al. 1994. The human kidney low affinity Na/ glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D- glucose. J. Clin. Invest., 93: 397–404

10.Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E. & Belew, R.K. et al. 1998. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J. Comput. Chem., 19(14):1639-1662.

11.Tsoong, P.C. & Ma, C.Y. 1981a. A study on the genus Sophora Linn. Acta Phytotax Sinica, 19: 1-22.

12.Liu, M., Liu, X.Y. & Cheng, J.F. 2003. Advance in the pharmacological research on matrine. Zhongguo Zhong Yao Za Zhi., 28: 801-804.

13.Zhang, Y.F., Wang, S.Z., Li, Y.Y., Xiao, Z.Y., Hu, Z.L. & Zhang, J.P. 2008. Sophocarpine and matrine inhibit the production of TNF and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon 26 adenocarcinoma in mice. Int. Immunopharmacol, 8: 1767- 1772.

14.Hu, Z.L., Zhang, J.P., Qian, D.H., Lin, W., Xie, W.F., Zhang, X.R. & Chen, W.Z. 1996a. Effects of matrine on mouse splenocyte proliferation and release of interleukin- 1 and -6 from peritoneal macrophages in vitro. Zhongguo Yao Li Xue Bao, 17: 259-261.

15.Hu, Z.L., Zhang, J.P., Wan, M.B., Yu, X.B., Lin, W. & Qian, D.H. 1996b. Effect of matrine on mouse hepatitis and tumour necrosis factor production induced by Propionibacterium acnes/ lipopolysaccharides. Zhongguo Yao Li Xue Bao, 31: 662665.

16.Hu, Z.L., Zhang, J.P., Yu, X.B., Lin, W., Qian, D.H. & Wan, M.B. 1996c. Effect of matrine on lipopolysaccharides/ Dgalactosamine-induced hepatitis and tumour necrosis factor release from macrophages in vitro. Zhongguo Yao Li Xue Bao, 17: 351-353.

17.Lin, W., Zhang, J.P., Hu, Z.L. & Qian, D.H. 1997. Inhibitory effect of matrine on lipopolysacchride induced tumor necrosis factor and interleukin-6 production from rat Kupffer cells. Yao Xue Xue Bao., 32: 93-96.

18.Xing, N.L., Sha, N., Yan, H.X., Pang, X.Y., Guan, S.H., Yang, M., Hua, H.M., Wu, L.J. & Guo, D.A. 2008. Isoprenylated flavonoids from the roots of Sophora tonkinensis. Phytochem Lett., 1: 163-167.

19.Tang, Y.P., Hu, J., Wang, J.H. & Lou, F.C. 2002. A new coumaronochromone from Sophora japonica. J. Asian Nat. Prod. Res., 4: 1-5.

20.Bach, M.K. & Brashler, J.R. 1975. Inhibition of IgE and compound 48/80-induced histamine release by lectins. Immunology, 29: 371-386.

21.Izaddoost, M. 1975. Alkaloid chemotaxonomy of the genus Sophora. Phytochemistry, 14: 203-204

22.Panthati Murali Krishna, Rao KNV, Sandhya S., David Banji. A review on phytochemical, ethnomedical and pharmacological studies on genus Sophora, Fabaceae: Revista Brasileira de Farmacognosia Brazilian Journal of Pharmacognosy; DOI: 10.1590/S0102-695X2012005000043

23.Amuthalekshmi, S. and Anton Smith, A. 2013. In silico design of piperazinone derivatives as DPP IV inhibitors in type II diabetes. Middle-East Journal of Scientific Research, 16(5): 580-586.

24.Amuthalekshmi, S. and Anton Smith, A. 2013. In silico design of a ligand for DPP IV in type II diabetes. Advances in Biological Research, 7(6): 248-252.

25.Manju, P.T., Anton Smith, A. & Padmaja, V. 2016. In silico Design of an SGLT2 Inhibitor in Diabetes mellitus; Middle- East Journal of Scientific Research, 24(10): 3108-3112.

26.Padmini, R., Reshma, K. & Sangeetha, K. 2017. In Silico Molecular Modeling and Docking Studies of Catharanthus roseus derived Alkaloids against GLUT4; Int. J. Curr. Res. Aca. Rev., Special Issue-4: 48-58.

27.Kalirajan, R., Pandiselvi, M., Sankar, S., Gowramma, B. Kalirajan, R., Pandiselvi, M., Sankar, S. & Gowramma, B. 2018. SF Journal of Pharmaceutical and Analytical Chemistry 1(1).